HK Stock Market Move | VIGONVITA-B(02630) once rose by over 14%, hitting a new high. Research has discovered that VV116 has potential for treating Nipah virus.

VIGONVITA-B(02630) surged over 14%, reaching a high of 112.7 Hong Kong dollars, hitting a new record high on the market. At the time of writing, it had risen by 12.02% to 110 Hong Kong dollars, with a trading volume of 12.9281 million Hong Kong dollars. On the news front, on January 26th after the market closed, the official WeChat account of the Wuhan Institute of Virology of the Chinese Academy of Sciences published an article stating that research teams led by researchers Xiao Gengfu/Zhang Leilei and researcher Shan Chao from the Wuhan Institute of Virology of the Chinese Academy of Sciences, in collaboration with Shanghai Institute of Materia Medica and Dr.Hu Tianwen from Jiyuan Jingkemiaonong Water Bio-pharmaceutical Co., Ltd., published an important research in an international journal confirming the significant antiviral activity of the oral nucleoside drug VV116 against Nipah virus, bringing new hope for the prevention and treatment of this highly lethal new emerging infectious disease. This research confirms for the first time the therapeutic potential of VV116 against the Nipah virus, which can not only be used as a preventive medication for high-risk groups such as healthcare workers and laboratory workers, but also provide a ready-made drug choice for the current and future Nipah virus outbreaks. Public information shows that Jiyuan Jingkemiaonong Water Bio-pharmaceutical Co., Ltd. was established in 2013, focusing on the three major treatment areas of neurology, reproductive health, and viral infections. In December last year, Jiyuan Jingkemiaonong Water announced the signing of a licensing and collaboration agreement with SIMCERE PHARMA. According to the agreement, Jiyuan Jingkemiaonong Water will grant SIMCERE PHARMA exclusive development, manufacturing, and commercialization rights for the indications of VV116 in respiratory syncytial virus (RSV) infection and human metapneumovirus (HMPV) infection in Greater China (including Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan region).